• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Dr Reddy’s announces launch of Colchicine Tablets USP in the US

expresspharmaJune 16, 2020

Tag: Dr Reddy , Colchicine Tablets , FDA

Dr Reddy’s Laboratories announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the US Food and Drug Administration (USFDA).

The Colcrys brand and generic market had US sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.

Dr Reddy’s Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.


Previous:Caplin Steriles gets USFDA approval for Phenylephrine Hydrochloride Injection USP

Next:Pricing problems: Aurobindo Pharma, Sun Pharma, Lupin named in lawsuit in US

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Dr Reddy’s announces launch of Colchicine Tablets USP in the US | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Nabumetone (FDA)

Nabumetone (FDA)
Irinotecan (FDA)

Irinotecan (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Deoxycyline (FDA)

Deoxycyline (FDA)
Clozapine (FDA)

Clozapine (FDA)
Bumetanide (FDA)

Bumetanide (FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
Sirolimus (FDA)

Sirolimus (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service